메뉴 건너뛰기




Volumn 25, Issue 6, 2015, Pages 1223-1227

Metabolic glycoengineering sensitizes drug-resistant pancreatic cancer cells to tyrosine kinase inhibitors erlotinib and gefitinib

Author keywords

Drug synergy; Epidermal growth factor receptor; Metabolic oligosaccharide engineering; Pancreatic cancer; Receptor tyrosine kinase inhibitor; Sialylation

Indexed keywords

ANTINEOPLASTIC AGENT; EPIDERMAL GROWTH FACTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; GEFITINIB; METABOLIC GLYCOENGINEERING DRUG; STAT PROTEIN; UNCLASSIFIED DRUG; PROTEIN KINASE INHIBITOR; QUINAZOLINE DERIVATIVE;

EID: 84923920602     PISSN: 0960894X     EISSN: 14643405     Source Type: Journal    
DOI: 10.1016/j.bmcl.2015.01.060     Document Type: Article
Times cited : (29)

References (45)


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.